📰 Virtual Poster News
Virtual Poster News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Virtual Poster. Real-time updates on events, politics, business and more.
May 9, 2023
/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration...
February 27, 2023
Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments...
January 9, 2023
Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple...
October 25, 2022
/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic...
October 19, 2022
Cypress, CA (PRWEB) October 19, 2022 -- AAGL Global Congress registration is filling at a record-breaking pace as the global association prepares to welcome
September 27, 2022
EQS-News: ABIVAX / Key word(s): MiscellaneousABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022 27.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax abstract on obefazimod phase 2b results selected for moderate...
September 27, 2022
Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance
September 27, 2022
EQS-News: ABIVAX / Key word(s): Miscellaneous ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATI...
July 29, 2022
Berlin, Germany (PRWEB) July 30, 2022 -- Life Molecular Imaging (LMI) announces today that new research results on its approved and investigational positron
February 26, 2021
Session Dates: Friday, February 26 – Monday, March 1, 2021 Session Location: Virtual Poster Hall Poster No: L30 About ADMA Biologics, Inc. ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Dr...